|Title of the trial||Diagnosis|
|An open-label, multi-center, expanded access study of oral AMN107 in adult patients with imatinib- (Glivec(R)/Gleevec(R)) -resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase||chronic myeloid leukemia|
|A pivotal, randomised study of lonafarnib (SCH 66336) versus placebo in the treatment of subjects with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who are platelet transfusion dependent, with or without anemia||myelodysplastic syndrome or chronic myelomonocytic leukemia|
|A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who are Resistant or Intolerant to Imatinib Mesylate (Gleevec(R))||myelogenous leukemia|
|A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib Mesylate (Gleevec)||myeloid leukemia|
|GvHD prophylaxis with ATG-Fresenius S in allogeneic stem cell transplantation from matched unrelated donors: a randomised phase III multi-center trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional transplant ATG-Fresenius S||acute lymphoblastic/myeloid leukemia, myelodysplastic syndrome|
2010 © SÚKL. Šrobárova 48, 100 41 Praha 10, +420 272 185 111, posta@suklcz.